Erhan Keles

Erhan Keles

Auto-generated profile, based on publicly available information

Erhan Keles

Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
EKErhan Keles
Erhan Keles
YSYang Song
Yang Song
DDDan Du
Dan Du
WDWen-Ji Dong
Wen-Ji Dong
YLYuehe Lin
Yuehe Lin
Nanotechnology-based gene delivery is the division of nanomedicine concerned with the synthesis, characterization, and functionalization of nanomaterials to be used in targeted-gene delivery applications. Nanomaterial-based gene delivery systems hold great promise for curing fatal inherited and acquired diseases, including neurological disorders, cancer, cardiovascular diseases, and acquired immunodeficiency syndrome (AIDS). However, their use in clinical applications is still controversial. To date, the Food and Drug Administration (FDA) has not approved any gene delivery system because of the unknown long-term toxicity and the low gene transfection efficiency of nanomaterials in vivo. Compared to viral vectors, nonviral gene delivery vectors are characterized by a low preexisting immunogenicity, which is important for preventing a severe immune response. In addition, nonviral vectors provide higher loading capacity and ease of fabrication. For these reasons, this review article focuses on applications of nonviral gene delivery systems, including those based on lipids, polymers, graphene, and other inorganic nanoparticles, and discusses recent advances in nanomaterials for gene therapy. Methods of synthesizing these nanomaterials are briefly described from a materials science perspective. Also, challenges, critical issues, and concerns about the in vivo applications of nanomaterial-based gene delivery systems are discussed. It should be noted that this article is not a comprehensive review of the literature.

14 November 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SCSung Hugh Choi
Sung Hugh Choi
DSDaniel W. Stuckey
Daniel W. Stuckey
SPSara Pignatta
Sara Pignatta
CRClemens Reinshagen
Clemens Reinshagen
JKJasneet Kaur Khalsa
Jasneet Kaur Khalsa
KSKhalid Shah
Khalid Shah
Purpose: Despite tumor resection being the first-line clinical care for glioblastoma (GBM) patients, nearly all preclinical immune therapy models intend to treat established GBM. Characterizing cytoreductive surgery-induced immune response combined with the administration of immune cytokines has the potential of offering a new treatment paradigm of immune therapy for GBMs. Experimental Design: We developed syngeneic orthotopic mouse GBM models of tumor resection and characterized the immune response of intact and resected tumors. We also created a highly secretable variant of immune cytokine IFNβ to enhance its release from engineered mouse mesenchymal stem cells (MSC-IFNβ) and assessed whether surgical resection of intracranial GBM tumor significantly enhanced the antitumor efficacy of targeted on-site delivery of encapsulated MSC-IFNβ. Results: We show that tumor debulking results in substantial reduction of myeloid-derived suppressor cells (MDSC) and simultaneous recruitment of CD4/CD8 T cells. This immune response significantly enhanced the antitumor efficacy of locally delivered encapsulated MSC-IFNβ via enhanced selective postsurgical infiltration of CD8 T cells and directly induced cell-cycle arrest in tumor cells, resulting in increased survival of mice. Utilizing encapsulated human MSC-IFNβ in resected orthotopic tumor xenografts of patient-derived GBM, we further show that IFNβ induces cell-cycle arrest followed by apoptosis, resulting in increased survival in immunocompromised mice despite their absence of an intact immune system. Conclusions: This study demonstrates the importance of syngeneic tumor resection models in developing cancer immunotherapies and emphasizes the translational potential of local delivery of immunotherapeutic agents in treating cancer. Clin Cancer Res; 23(22); 7047–58. ©2017 AACR.

7 June 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DRDenise Rageot
Denise Rageot
TBThomas Bohnacker
Thomas Bohnacker
EKErhan Keles
Erhan Keles
JMJacob A. McPhail
Jacob A. McPhail
RHReece M. Hoffmann
Reece M. Hoffmann
MWMatthias WYMANN
Matthias WYMANN
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth, proliferation, survival and metastasis. Here, we report a SAR-study which led to the discovery of a drug-like ATP-site PI3K/mTOR kinase inhibitor: (S)-4-(difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530) (6), which qualifies as a clinical candidate due to its potency and specificity for PI3K and mTOR kinases, and its pharmacokinetic properties, including brain penetration. PQR530 (6) showed excellent selectivity over a wide panel of kinases and an excellent selectivity against unrelated receptor enzymes and ion channels. Moreover, compound PQR530 (6) prevented cell growth in a cancer cell line panel. The preclinical in vivo characterization of compound PQR530 (6) in an OVCAR-3 xenograft model demonstrated good oral bioavailability, excellent brain penetration, and efficacy. Initial toxicity studies in rats and dogs qualify PQR530 (6) for further development as a therapeutic agent in oncology.

3 September 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
Chiara BorsariChiara Borsari
Chiara Borsari
DRDenise Rageot
Denise Rageot
FBFlorent Beaufils
Florent Beaufils
TBThomas Bohnacker
Thomas Bohnacker
EKErhan Keles
Erhan Keles
MWMatthias WYMANN
Matthias WYMANN
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we have developed a novel anticancer agent, the potent pan-PI3K inhibitor PQR514 (4), which is a follow-up compound for the phase-II clinical compound PQR309 (1). Compound 4 has an improved potency both in vitro and in cellular assays with respect to its predecessor compounds. It shows superiority in the suppression of cancer cell proliferation and demonstrates significant antitumor activity in an OVCAR-3 xenograft model at concentrations approximately eight times lower than PQR309 (1). The favorable pharmacokinetic profile and a minimal brain penetration promote PQR514 (4) as an optimized candidate for the treatment of systemic tumors.

12 January 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
Chiara BorsariChiara Borsari
Chiara Borsari
EKErhan Keles
Erhan Keles
ATAndrea Treyer
Andrea Treyer
MPMartina De Pascale
Martina De Pascale
PHPaul Hebeisen
Paul Hebeisen
MWMatthias WYMANN
Matthias WYMANN
Highly selective mTOR inhibitors have been discovered through the exploration of the heteroaromatic ring engaging the binding affinity region in mTOR kinase. Compound 11 showed predicted BBB permeability in a MDCK-MDR1 permeability in vitro assay, being the first pyrimido-pyrrolo-oxazine with potential application in the treatment of neurological disorders.

12 November 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
LBLukas Bissegger
Lukas Bissegger
TCTheodora Alexandra Alexandra Constantin
Theodora Alexandra Alexandra Constantin
EKErhan Keles
Erhan Keles
LRLuka Raguž
Luka Raguž
IBIsobel Barlow-Busch
Isobel Barlow-Busch
MWMatthias WYMANN
Matthias WYMANN
Optimised covalent PI3Kα chemical probes designed for rapid cellular diffusion enable efficient and sustained target engagement, providing a clearer view of cancer cell signaling networks.